NFKB1 and lung carcinoma: However, in A549 and H1975 human lung cancer cell lines, C93 treatment triggered a protective response mediated by NF-kB signaling activation, and the pharmacological inhibition of both NF-kB and FASN led to more effective cell killing than inhibiting either NF-kB or FASN individually [99].